Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

Brain metastases are the most common cause of death in patients with metastatic melanoma, and the RAF-MEK-ERK and PI3K-AKT signaling pathways are key players in melanoma progression and drug resistance. The BRAF inhibitor vemurafenib significantly improved overall survival. However, brain metastases...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Niessner, Heike, Forschner, Andrea, Klumpp, Bernhard, Honegger, Jürgen B., Witte, Maria, Bornemann, Antje, Dummer, Reinhard, Adam, Annemarie, Bauer, Jürgen, Tabatabai, Ghazaleh, Flaherty, Keith, Sinnberg, Tobias, Beck, Daniela, Leiter, Ulrike, Mauch, Cornelia, Roesch, Alexander, Weide, Benjamin, Eigentler, Thomas, Schadendorf, Dirk, Garbe, Claus, Kulms, Dagmar, Quintanilla-Martinez, Leticia, Meier, Friedegund
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Ltd 2013
Aiheet:
Clinical Cancer Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3797558/
https://ncbi.nlm.nih.gov/pubmed/24133630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.50
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia